Patient with novel coronavirus deceased An 86-year-old man who was hospitalised in the Ikazia hospital Rotterdam with COVID-19 has died. The source of infection of the patient remains unknown.
Eight new patients, Maasstad Hospital closes ICU department To date, Monday 2 March, eight new patients have been reported to RIVM. This brings the total number of positive tests in the Netherlands to 18.
Three new patients with novel coronavirus (COVID-19) Three new patients were diagnosed with the novel coronavirus (COVID-19) on March 1st, bringing the number of coronavirus patients in the Netherlands to ten.
Patient with COVID-19 in Delft On 29 February, a woman in Delft was diagnosed with the novel coronavirus (COVID-19) in the Netherlands. The woman had been in Lombardy, in Northern Italy, last week.
Summary International Expert Meeting on breast implant-associated lymphoma On November 19th 2018, RIVM organised an international expert meeting on a rare type of lymphoma that is associated with breast implants.
No decline in CO2 emissions since 1990 Dutch greenhouse gas emissions were 13 per cent lower in 2017 than in 1990. Emissions have been almost constant over the past five years.
RIVM will make measurements around the Sint Maarten landfill From 21 January 2019, a team from RIVM will travel to Sint Maarten to make measurements and take samples at various locations around the landfill in Philipsburg.
Explanation for difference in development ammonia emissions and concentrations Since 2005, higher ammonia concentrations have been measured in the air, despite registered emissions decreasing. New RIVM research shows that three-quarters of this difference can be explained by changes in atmospheric and chemical processes.
Citizen science network produces accurate maps of fine air particles Measurements by thousands of citizen scientists in the Netherlands using their smartphones and the iSPEX add-on are delivering accurate data on fine air particles in the atmosphere that add valuabl
Sustainability of EU regulatory system on medicinal products In safeguarding the quality, safety and efficacy of medicinal products, the present EU regulatory system has become a time consuming and highly regulated process.